Sector News

Medtronic-Covidien merger imminent after Irish court’s OK

January 26, 2015
Life sciences
The Irish High Court has approved the $43 billion merger between Medtronic Inc. and Ireland’s Covidien, clearing the way for the deal to close later today.
 
Medtronic and Covidien announced the court’s decision this morning. They will combine in a new company called Medtronic plc that’s legally based in Dublin, though its management remains at Medtronic’s current headquarters in Fridley, Minn. The two companies’ shares will continue to trade normally today, with the new stock starting to trade Tuesday.
 
Shareholders of the two companies approved the deal earlier this month.
 
The medical-device giant announced in June it would buy Dublin-based medical-products manufacturer Covidien.
 
By Mark Reilly
 

Related News

March 6, 2021

Takeda takes full control of drug for rare epilepsies

Life sciences

The deal inked with New York-based Ovid Therapeutics carries an almost $200 million upfront payment and could be worth as much as $856 million provided the medicine, known as soticlestat, hits certain milestones. 

March 6, 2021

Novartis signs Covid-19 vaccine manufacturing agreement with CureVac

Life sciences

Novartis has entered an initial agreement to manufacture the mRNA and bulk drug product for CureVac’s Covid-19 vaccine candidate, CVnCoV.

March 6, 2021

Disney teams with Philips to bring its characters to pediatric imaging

Life sciences

A whole new world: Philips and the Walt Disney Company will use animated shorts featuring some of Disney’s most famous characters in customized stories created with clinical guidance from Philips.

Send this to a friend